🚀 VC round data is live in beta, check it out!
Baumer Valuation Multiples
Discover revenue and EBITDA valuation multiples for Baumer and similar public comparables like Sequana Medical, SMAIO, Mentice, Biohit and more.
Baumer Overview
About Baumer
Baumer SA develops solutions in hospitals and health industry equipments. It has various segments like Orthopedic Implants, Biomaterials, Sterilization, Infections Control, Surgical Centers, Water Treatment and solid residuals Health Treatment Divisions. The company also provides surgical center solutions, including anesthesia systems, lighting products, surgical tables, and orthopedic solutions consisting of hip and knee prosthesis, shoulder prosthesis, non-conventional orthopedic solutions, intramedullary fixation solutions, external and internal fixations, and biomaterials. In addition, it offers spine solutions, such as fixation system locks, occipitocervial fixation systems, angled cervical cages, and posterior lumbar cages.
Founded
1952
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$31M
Baumer Financials
Baumer reported last fiscal year revenue of $42M and EBITDA of $9M.
In the same fiscal year, Baumer generated $26M in gross profit, $9M in EBITDA, and $4M in net income.
Baumer P&L
In the most recent fiscal year, Baumer reported revenue of $42M and EBITDA of $9M.
Baumer expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $42M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $26M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 63% | XXX | XXX | XXX |
| EBITDA | — | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 18% | XXX | XXX | XXX |
| Net Profit | — | XXX | $4M | XXX | XXX | XXX |
| Net Margin | — | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Baumer Stock Performance
Baumer has current market cap of $45M, and enterprise value of $31M.
Market Cap Evolution
Baumer's stock price is $4.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31M | $45M | 0.4% | XXX | XXX | XXX | $0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBaumer Valuation Multiples
Baumer trades at 0.7x EV/Revenue multiple, and 3.4x EV/EBITDA.
Baumer Financial Valuation Multiples
As of April 8, 2026, Baumer has market cap of $45M and EV of $31M.
Equity research analysts estimate Baumer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Baumer has a P/E ratio of 12.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV (current) | $31M | XXX | $31M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 4.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.2x | XXX | XXX | XXX |
| P/E | — | XXX | 12.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Baumer Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Baumer Margins & Growth Rates
Baumer's revenue in the last fiscal year grew by 10%.
Baumer Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (13%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Baumer Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sequana Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| SMAIO | XXX | XXX | XXX | XXX | XXX | XXX |
| Mentice | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Trajan Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Baumer M&A Activity
Baumer acquired XXX companies to date.
Last acquisition by Baumer was on XXXXXXXX, XXXXX. Baumer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Baumer
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBaumer Investment Activity
Baumer invested in XXX companies to date.
Baumer made its latest investment on XXXXXXXX, XXXXX. Baumer invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Baumer
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Baumer
| When was Baumer founded? | Baumer was founded in 1952. |
| Where is Baumer headquartered? | Baumer is headquartered in Brazil. |
| Is Baumer publicly listed? | Yes, Baumer is a public company listed on B3. |
| What is the stock symbol of Baumer? | Baumer trades under BALM4 ticker. |
| When did Baumer go public? | Baumer went public in 2005. |
| Who are competitors of Baumer? | Baumer main competitors are Sequana Medical, SMAIO, Mentice, Biohit. |
| What is the current market cap of Baumer? | Baumer's current market cap is $45M. |
| What is the current revenue of Baumer? | Baumer's last fiscal year revenue is $42M. |
| What is the current EV/Revenue multiple of Baumer? | Current revenue multiple of Baumer is 0.7x. |
| Is Baumer profitable? | No, Baumer is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.